Q-omics provides the consensus-scored TMEM59 profile across patient tissues and cancer cell-line models. TMEM59 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM59 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, TMEM59 protein abundance shows 28,041 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, KIRP, and LUAD as cancer lineages where TMEM59 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM59 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM59 survival associations across molecular data types. TMEM59 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM59 RNA expression–survival associations across cancer types. High TMEM59 expression shows unfavorable associations in LGG, KIRP, LIHC, SCLC and HNSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM59 RNA expression.
This table summarizes TMEM59 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM59. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM59 shows lower tumor expression in KIRP, KICH, COAD, LUSC and THCA and higher tumor expression in LIHC. The KIRP box plot shows higher TMEM59 RNA expression in normal versus tumor tissue (log2 FC = −1.007, t-test p < 0.001).
This table shows molecular features associated with TMEM59 in patient tissues and cancer cell lines. In patient samples, TMEM59 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM59 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
